| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Atractylenolide II targets cell cycle regulation and proliferation pathways. It inhibits proliferation and halts the cell cycle at the G2/M phase in some cell lines. It induces apoptosis in cancer cells. Its precise molecular targets are still being investigated.
|
|---|---|
| ln Vitro |
In vitro, Atractylenolide II has anti-proliferative activity. It induces G1 cell cycle arrest in B16 melanoma cells. It also inhibits proliferation and halts the cell cycle at the G2/M phase in other cell lines. It induces apoptosis in cancer cells.
|
| ln Vivo |
In vivo activity data for Atractylenolide II are limited. Its anti-inflammatory and anti-tumor activities suggest potential in vivo efficacy in models of inflammation and cancer. Further in vivo studies are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
In vitro cell proliferation assays for Atractylenolide II are performed using B16 melanoma cells or other cancer cell lines. Cells are seeded in 96-well plates and treated with compound concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Cell cycle analysis is performed by flow cytometry.
|
| Cell Assay |
In vitro cellular assays for Atractylenolide II are performed using B16 melanoma cells or other cancer cell lines. Cells are treated with compound concentrations ranging from 0.1 to 100 µM for 24-72 hours. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining or by measuring caspase-3/7 activity.
|
| Animal Protocol |
In vivo animal studies for Atractylenolide II would typically utilize rodent models of cancer or inflammation. Tumor xenograft models are used to assess antitumor efficacy. The compound is administered orally or intraperitoneally. Endpoints include tumor growth, survival, and histopathology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Atractylenolide II are not well characterized. The compound has a molecular weight of 232.32. It is soluble in DMSO (10 mM). Standard PK studies in rodents would be required to determine half-life, bioavailability, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Toxicological data for Atractylenolide II are limited. As a natural product-derived compound, it may have a moderate safety profile. No significant acute toxicity has been reported. Standard toxicity screening would involve acute and repeated-dose studies in rodents.
|
| References | |
| Additional Infomation |
Atractylenolide II is a sesquiterpene lactone. It has been reported to exist in Codonopsis pilosula, Calendula officinalis, and other organisms with relevant data.
Atractylenolide II is a sesquiterpenoid from Atractylodes macrocephala with anti-proliferative activity, inducing G1 cell cycle arrest in B16 melanoma cells. It also exhibits anti-inflammatory and anti-tumor effects. It is not clinically approved and is used as a research tool. |
| Molecular Formula |
C₁₅H₂₀O₂
|
|---|---|
| Molecular Weight |
232.32
|
| Exact Mass |
232.146
|
| CAS # |
73069-14-4
|
| PubChem CID |
14448070
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
378.0±41.0 °C at 760 mmHg
|
| Flash Point |
158.7±25.0 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.535
|
| LogP |
3.61
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=C2C[C@H]3C(=C)CCC[C@@]3(C[C@@H]2OC1=O)C
|
| InChi Key |
OQYBLUDOOFOBPO-KCQAQPDRSA-N
|
| InChi Code |
InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h12-13H,1,4-8H2,2-3H3/t12-,13-,15+/m0/s1
|
| Chemical Name |
(4aS,8aR,9aS)-3,8a-dimethyl-5-methylene-4a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2(4H)-one
|
| Synonyms |
2 AtractylenolideAsterolideAtractylenolide II 2Atractylenolide2-Atractylenolide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~430.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3044 mL | 21.5220 mL | 43.0441 mL | |
| 5 mM | 0.8609 mL | 4.3044 mL | 8.6088 mL | |
| 10 mM | 0.4304 mL | 2.1522 mL | 4.3044 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
